Abstracts tagged "Disease Activity and SLE"

Abstract Number: 1677 • 2018 ACR/ARHP Annual Meeting
Evaluation of Erythrocyte Sedimentation Rate As a Marker of Disease Activity in Patients with Systemic Lupus Erythematosus
Bobby Kwanghoon Han¹, Elizabeth Rathwell¹, Bernard Ng¹ and Mark Wener², ¹Division of rheumatology, University of Washington, Seattle, WA, ²Division of Rheumatology, Department of Laboratory Medicine, University of Washington, Seattle, WA
Background/Purpose: SLEDAI is a global disease activity index for SLE and includes anti-DNA and complement levels. However, elevated anti-DNA or low C3 & C4 levels…
Abstract Number: 1630 • 2017 ACR/ARHP Annual Meeting
Achievement of Lupus Low Disease Activity State (LLDAS) in the Early Phase of Systemic Lupus Erythematosus Prevent Damage Accrual
Matteo Piga, Alberto Floris, Giulia Cappellazzo, Alessandro Mathieu and Alberto Cauli, Unit and Chair of Rheumatology, University Hospital of Cagliari, Cagliari, Italy
Background/Purpose: The Asia-Pacific Collaboration Group has recently proposed the definition of Lupus Low Disease Activity state (LLDAS). This potential target in SLE treatment has been…
Abstract Number: 1794 • 2016 ACR/ARHP Annual Meeting
The High Disease Activity State Is an Adverse Prognostic Indicator in SLE and Defines a Clinically Distinct Population
Rachel Koelmeyer¹, Eric F Morand^2,3 and Alberta Y. Hoi^2,3, ¹Centre for Inflammatory Diseases, Monash University, Clayton VIC, Australia, ²Centre for Inflammatory Diseases, Monash University, Melbourne, Australia, ³Department of Rheumatology, Monash Health, Clayton VIC, Australia
Background/Purpose: The heterogeneity of SLE in terms of disease characteristics is an issue not only for the diagnostic process but also for disease management. Previously,…
Abstract Number: 2927 • 2015 ACR/ARHP Annual Meeting
Disease Activity Patterns over Time in Patients with SLE – a Retrospective Descriptive Analysis of the Hopkins Lupus Cohort
Noémi Györi¹, Katerina Chatzidionysiou², Laurence S Magder³, Ronald F. van Vollenhoven¹ and Michelle Petri⁴, ¹Department of Medicine, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden, ²Department of Medicine, Unit of Rheumatology, Department of Medicine Solna, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ³Johns Hopkins University School of Medicine, Devision of Rheumatology, Baltimore, MD, ⁴Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a multi-systemic inflammatory disease, characterized by an extreme variability of its expression, both between and within individuals, over time.…
Abstract Number: 716 • 2014 ACR/ARHP Annual Meeting
Simple Disease Assessment for People with Lupus Erythematosus
Meenakshi Jolly¹, Winston Sequeira², Sergio Toloza³, Ana M. Bertoli⁴, Luis M. Vilá⁵, Ivana Blazevic⁶, Ioana Moldovan⁷, Karina D Torralba⁸, Berna Goker⁹, Josiane Bourré-Tessier¹⁰, Sandra V. Navarra¹¹, Daniel Wallace¹², Michael H. Weisman¹³, Ann E. Clarke¹⁴, Chi Chiu Mok¹⁵ and Joel A. Block¹, ¹Rheumatology, Rush University Medical Center, Chicago, IL, ²Medicine/Rheumatology, Rush University, Chicago, IL, ³Hospital San Juan Bautista, San Fernando del Valle de Catamarca, Argentina, ⁴Instituto Reumatológico Strusberg, Cordoba, Cordoba, Argentina, ⁵Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus, San Juan, PR, ⁶University of Buenos Aires, Buenos Aries, Argentina, ⁷Rheumatology, Beaver Medical Group, Redlands, CA, ⁸University of Southern California, LA, CA, ⁹Department of Internal Medicine- Rheumatology, Gazi University School of Medicine, Ankara, Turkey, ¹⁰Department of Medicine, Division of Rheumatology, Centre Hospitalier de l’Université de Montréal, Montreal, QC, Canada, ¹¹University of Santo Tomas Hospital, Manila, Philippines, ¹²UCLA, LA, CA, ¹³Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ¹⁴Division of Rheumatology, University of Calgary, Calgary, AB, Canada, ¹⁵Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong
Background/Purpose: Community rheumatologists treating patients with Systemic Lupus Erythematosus (SLE) typically lack user-friendly tools to effectively track SLE disease activity. Current disease activity tools in…
Abstract Number: 2531 • 2013 ACR/ARHP Annual Meeting
Elevated Combined Serum Free Light Chains Are Associated With Active Disease In Systemic Lupus Erythematosus
Lakhvir Kaur Assi¹, Larissa Lisnevskaia², Emma Ross³, Richard G Hughes¹, Anisur Rahman⁴ and David A. Isenberg⁵, ¹Clinical R+D, The Binding Site Group Ltd, Birmingham, United Kingdom, ²Oshawa Clinic, Oshawa, ON, Canada, ³Centre for Rheumatology, University College London, London, United Kingdom, ⁴Centre for Rheumatology Research,Rayne Institute, 4th Floor, University College London, London, United Kingdom, ⁵Centre for Rheumatology Research, Rayne Building, 4th Floor, Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom
Background/Purpose: Chronic and hyper-stimulated B cells are characteristics commonly found in patients with systemic lupus erythematosus (SLE). Due to the complexity and variability observed during…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].